As European markets navigate the complexities of geopolitical tensions and fluctuating energy prices, the pan-European STOXX Europe 600 Index has managed a modest gain, reflecting cautious optimism amid uncertainty. In this environment, selecting high-growth tech stocks requires a focus on companies with robust innovation capabilities and resilience to external shocks, as these attributes can help them thrive despite broader economic challenges.
Top 10 High Growth Tech Companies In Europe
| Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
| Hacksaw |
24.17% |
25.33% |
★★★★★★ |
| Pharma Mar |
16.75% |
29.35% |
★★★★★☆ |
| Adtraction Group |
4.79% |
101.86% |
★★★★★☆ |
| Shoper |
13.84% |
22.28% |
★★★★★☆ |
| Paradox Interactive |
5.65% |
37.82% |
★★★★★☆ |
| Appear |
20.02% |
25.75% |
★★★★★★ |
| Bonesupport Holding |
21.85% |
33.95% |
★★★★★★ |
| CD Projekt |
32.85% |
28.82% |
★★★★★☆ |
| SyntheticMR |
18.81% |
47.40% |
★★★★★☆ |
| Waystream Holding |
12.91% |
40.25% |
★★★★★☆ |
We're going to check out a few of the best picks from our screener tool.
Kitron
Simply Wall St Growth Rating:★★★★★☆
Overview:Kitron ASA is an electronics manufacturing services provider operating in multiple countries including Norway, Sweden, and the United States with a market capitalization of NOK20.10 billion.
Operations:Kitron ASA generates revenue primarily through electronics manufacturing services across various sectors, including defense, energy, telecommunications, and medical devices. The company operates in several countries such as Norway, Sweden, Denmark, and the United States. With a focus on high-quality production and efficient supply chain management, Kitron has demonstrated a net profit margin of 6.5%.
Kitron's strategic moves in the defense sector, evidenced by a recent EUR 16 million order, align with its ambitious revenue target of EUR 1.5 billion. In 2025, the company showcased robust financial health with a significant jump in quarterly sales to EUR 233.8 million from EUR 160.6 million and an annual net income rise to EUR 43.8 million from EUR 28 million previously. These figures underline Kitron's strong market position and operational efficiency, further supported by an optimistic revenue forecast for 2026 set between EUR 900 million and EUR 1050 million, surpassing previous expectations.
-
Click here and access our complete health analysis report to understand the dynamics of Kitron.
-
Gain insights into Kitron's historical performance by reviewing our past performance report.
Vend Marketplaces
Simply Wall St Growth Rating:★★★★☆☆
Overview:Vend Marketplaces ASA, along with its subsidiaries, operates a range of marketplaces across Sweden, Norway, Denmark, Finland, and Poland with a market capitalization of NOK49 billion.
Operations:Vend Marketplaces ASA generates revenue primarily through its diverse marketplace operations, with significant contributions from Mobility (NOK2.54 billion) and Real Estate (NOK1.33 billion) segments.
Despite a challenging year marked by a net loss of NOK 166 million, Vend Marketplaces ASA remains poised for recovery with projected revenue growth at 8.6% annually, outpacing the Norwegian market's average of 2.7%. The company's focus on enhancing shareholder value is evident from its recent dividend increase to NOK 2.50 per share. With earnings expected to surge by 62.82% annually, Vend's strategic adjustments and robust market positioning signal potential for significant financial improvement in the coming years.
-
Dive into the specifics of Vend Marketplaces here with our thorough health report.
-
Explore historical data to track Vend Marketplaces' performance over time in our Past section.
Kuros Biosciences
Simply Wall St Growth Rating:★★★★★☆
Overview:Kuros Biosciences AG focuses on the commercialization and development of biologic technologies for musculoskeletal care, operating in the United States, European Union, and internationally, with a market cap of CHF846.19 million.
Operations:Kuros Biosciences AG generates revenue primarily from its medical devices segment, which accounts for $146.06 million. The company is involved in the commercialization and development of biologic technologies aimed at musculoskeletal care across multiple regions including the United States and European Union.
Kuros Biosciences AG has demonstrated a remarkable turnaround, transitioning from a net loss to reporting a net income of USD 2.55 million and substantial revenue growth from USD 85.16 million to USD 146.06 million within a year. This surge reflects an annualized revenue increase of 23.9% and an earnings spike projected at 58% annually over the next three years, significantly outpacing the broader Swiss market's growth rates. The company's aggressive R&D investment strategy is paying dividends, fostering innovations that propel them ahead in the competitive biotech landscape. With guidance projecting sales reaching up to USD 330 million by 2028, Kuros is not just recovering but potentially reshaping its sector's dynamics.
-
Navigate through the intricacies of Kuros Biosciences with our comprehensive health report here.
-
Gain insights into Kuros Biosciences' past trends and performance with our Past report.
Next Steps
-
Discover the full array of 53 European High Growth Tech and AI Stocks right here.
-
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
-
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Ready To Venture Into Other Investment Styles?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
-
Find companies with promising cash flow potential yet trading below their fair value .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OB:KIT OB:VEND and SWX:KURN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
